slides · global inventory
Diagram
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 23,622
Current window 16,201-16,230
Pages 788
Rows per page 30
Component
16,201-16,230 of 23,622
16
The central icon represents the Hyperfine device, surrounded by five supporting pillars of the ecosystem.Hyperfine | Investor Presentation Deck | 24 slides · Hyperfine
Conference presentation Investor relations 1 hit
03
The slide uses a hub-and-spoke diagram with a central image of a fuel cell stack.Hyzon | Results Presentation Deck | 15 slides · Hyzon
Conference presentation Investor relations 1 hit
04
Uses a vertical timeline-style list to organize four key business pillars.Hyzon | Results Presentation Deck | 15 slides · Hyzon
Conference presentation Investor relations 1 hit
11
The slide uses a process flow diagram to show how different AI capabilities contribute to productivity, quality, and volume boosts.IBEX | Investor Presentation Deck | 18 slides · ibex
Pitch deck Investor relations Beat · Rising SuccessLoop · Quick Win Big Bet1 hit
04
The slide uses a vertical timeline structure to organize clinical catalysts by asset.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Problem1 hit
05
The slide uses a split-screen visual comparison to contrast traditional antibody approaches with the company's TCR-based platform.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Problem1 hit
11
The slide uses a table to show market opportunity (prevalence) and a diagram to illustrate the mechanism of action for two different drug platforms.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Solution1 hit
15
Includes clinical trial screening data for specific cancer types.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
18
The slide uses a process-flow diagram to distinguish between two generations of TCR-T therapies and their respective trial phases.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
36
The left side uses a funnel diagram to represent the manufacturing process steps.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
42
The slide outlines a manufacturing process for off-the-shelf cell therapy.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
50
The slide uses a horizontal arrow-based process flow to categorize programs by development stage (Clinical vs Preclinical).Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
52
Includes study design timeline, histology details, and comparative tumor volume charts (group averages vs individual mice).Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
53
The slide illustrates the methodology for PK analysis (injection, sampling, quantification) and presents the resulting concentration-time curve.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
54
The slide uses a process flow diagram to illustrate the transition from dose escalation to expansion cohorts.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
58
The slide outlines a standard clinical trial progression from overview to dose escalation and expansion.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
61
The funnel is represented as a series of concentric circles/segments.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
63
The slide illustrates the mechanism of action for two therapeutic modalities derived from the same TCR discovery platform.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
64
The slide uses a comparative framework to explain the safety profile of their technology platform.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations 1 hit
06
Includes a biological process diagram showing B-cell development and target markers (CD19, CD20, BCMA).Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
07
Uses a hub-and-spoke diagram to illustrate the central problem of neurotoxicity and its four primary negative consequences.Immix Biopharma | Investor Presentation Deck | 60 slides · Immix Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
Includes a cartoon illustration of a cell/virus character.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
09
The slide uses a diagram to map specific protein domains to their functional benefits.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
13
Includes a cartoon mascot at the bottom.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
38
The slide uses a step-wise diagram to illustrate dose escalation in a clinical trial setting.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
40
Includes scientific diagrams of molecular pathways, penetration depth charts, and efficacy metrics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
42
Includes a process flow diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
48
Shows two parallel clinical development tracks: monotherapy and combination with tislelizumab.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
54
Includes multiple citations and diagrams illustrating the mechanism of action and clinical results.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
58
The process flow is non-linear, moving left-to-right on the top row (1-5) and right-to-left on the bottom row (6-10).Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations 1 hit